Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma

Summary

This is a multicenter, single arm, phase 2 study designed to evaluate the efficacy and safety of cetuximab for the treatment of advanced (unresectable)/metastatic, chordoma. The target patient population will be any chordoma patient 18 years of age with locally unresectable disease or metastatic disease.

Timeline

Start

2022-05-27

Primary completion

2026-09-01

Completion

2026-09-01

Drugs

Indications